HIV gag peptide (197-205) is a H-2Kd-restricted epitope derived from the p24 portion of the HIV-1 gag protein, consists of amino acids 197-205 (AMQMLKETI).
HIV gag peptide 197-205 is a synthetic peptide fragment corresponding to amino acids 197 through 205 of the HIV-1 group-specific antigen (gag) polyprotein. As a defined epitope derived from the p24 region of the gag protein, it is widely recognized for its immunological relevance in the study of HIV biology and host-pathogen interactions. The peptide's sequence specificity and structural features make it a valuable tool for dissecting cellular and molecular mechanisms underpinning immune recognition, viral assembly, and antigen processing. Researchers leverage this peptide to explore fundamental questions in virology, immunology, and vaccine development, as well as to develop and validate analytical assays.
Epitope mapping: Utilization of the HIV gag peptide 197-205 is central to epitope mapping studies aimed at identifying T-cell recognition sites within the HIV-1 gag protein. By exposing immune cells to this defined peptide, investigators can determine the presence, specificity, and functional characteristics of T-cell responses in various experimental models. This approach is instrumental in characterizing cytotoxic T lymphocyte (CTL) epitopes, elucidating immune escape mechanisms, and informing the rational design of vaccine candidates targeting conserved viral regions.
Immunological assay development: The peptide serves as a precise reagent in the development and optimization of immunological assays, including enzyme-linked immunospot (ELISpot), intracellular cytokine staining, and tetramer staining protocols. Such assays enable quantitative and qualitative assessment of HIV-specific T-cell responses in peripheral blood mononuclear cells or other immune cell populations. The use of this peptide fragment supports the validation of assay sensitivity and specificity, facilitating the monitoring of immune responses in both basic research and translational studies.
Antigen processing and presentation research: HIV gag peptide 197-205 is employed to investigate the cellular pathways responsible for antigen processing and major histocompatibility complex (MHC) class I presentation. By introducing the peptide into antigen-presenting cells, researchers can bypass endogenous processing steps and directly assess MHC-peptide complex formation, peptide binding affinity, and T-cell receptor engagement. These studies provide critical insights into the molecular determinants of immune recognition and inform strategies to enhance antigen presentation for vaccine and immunotherapy development.
Peptide-based vaccine research: The defined sequence and immunogenic properties of this peptide make it a model antigen for exploring peptide-based vaccine formulations. Researchers utilize it to evaluate immunogenicity, adjuvant efficacy, and delivery systems in preclinical immunization studies. The peptide's role in stimulating specific T-cell responses enables the assessment of candidate vaccine platforms and the optimization of peptide selection for multivalent vaccine constructs targeting HIV and related retroviruses.
Analytical standards and quality control: In addition to its research applications, the HIV gag peptide 197-205 is used as a reference standard for analytical method development and quality control in peptide synthesis and purification workflows. Its well-characterized sequence and physicochemical properties allow for the calibration of analytical instruments, validation of chromatographic methods, and benchmarking of synthetic peptide production processes. This ensures consistency, reproducibility, and reliability in experimental protocols involving synthetic peptides.
4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More